Convergent Therapeutics Announces Positive Phase 2 Data at ASCO 2026 Showing Promising Anti-Tumor Activity, Durability, and Favorable Tolerability for CONV01-α in Lu-PSMA-Exposed Metastatic Castration-Resistant Prostate Cancer (mCRPC)
News & media
Convergent Therapeutics to Present Largest Set of Prospective Phase 2 Data for an Alpha Radiopharmaceutical in Lu-PSMA-Exposed Metastatic Castration-Resistant Prostate Cancer at ASCO 2026
Convergent Therapeutics Names Andrew Davis Chief Business and Strategy Officer
Convergent Therapeutics to Present Phase 2 Data for CONV01-α in Lu-PSMA pretreated Metastatic Castration-Resistant Prostate Cancer Patients at the 2026 ASCO Annual Meeting
Convergent Therapeutics Appoints Radiopharmaceutical Industry Veteran Michael Rossi to its Board of Directors
Convergent Therapeutics Appoints Elizabeth L. Montgomery Chief People Officer
Convergent Therapeutics and NorthStar Medical Radioisotopes Announce Expanded Partnership to Support Convergent’s Late-Stage Alpha-Emitting Radioantibody Program
Convergent Therapeutics Announces Two Clinical Trial Updates on CONV01-α at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2025
Convergent Therapeutics Appoints Barbara Duncan to Board of Directors
Convergent Therapeutics Announces First Shipments of Actinium 225 from Cardinal Health to Support the CONVERGE-01 Phase 2 Clinical Trial